This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder’s Root Cause Rather Than Its Symptoms
By Sara Hashemi, Aug 18, 2026
Previous treatments for narcolepsy type 1 included stimulants to help patients stay awake and central nervous system depressants to alleviate cataplexy and improve nighttime sleep. But they only addressed symptoms of the disease. They acted more like a “patch” than a fix, says Alex Dimitriu, a psychiatrist and sleep physician at Menlo Park Psychiatry and Sleep Medicine, to Forbes’ Claire Wolters. Orzeyful, manufactured by the Japanese pharmaceutical company Takeda, instead works by restoring the body’s orexin cycle by mimicking the natural chemical.
Click HERE for the full article.
